Market Tracker

02/27 5:16pm ET

Ligand Pharmaceuticals Inc (NASDAQ:LGND)

107.38
Delayed Data
As of 4:00pm ET
 +7.00 / +6.97%
Today’s Change
87.50
Today|||52-Week Range
139.79
+5.68%
Year-to-Date
Ligand (LGND) Q4 Earnings Down Y/Y, Revenues Miss Estimates
Feb 24 / Zacks.com - Paid Partner Content
Forget Alexion, Buy these 4 Biotech Stocks Instead
Feb 20 / Zacks.com - Paid Partner Content
Drug Stocks Q4 Earnings Slated for Feb 23: BMRN, ICPT & More
Feb 22 / Zacks.com - Paid Partner Content
3 Biotechs With Tremendously Promising Pipelines
Feb 15 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close100.38
Today’s open99.29
Day’s range99.29 - 107.94
Volume989,897
Average volume (3 months)321,148
Market cap$2.1B
Dividend yield--
Data as of 4:00pm ET, 02/27/2017

Growth & Valuation

Earnings growth (last year)-101.02%
Earnings growth (this year)+98.45%
Earnings growth (next 5 years)+35.00%
Revenue growth (last year)+51.53%
P/E ratio383.5
Price/Sales19.42
Price/Book--

Competitors

 Today’s
change
Today’s
% change
AGIOAgios Pharmaceutical...+2.54+5.31%
PTLAPortola Pharmaceutic...+1.49+4.45%
SAGESAGE Therapeutics In...+6.51+10.45%
PRTAProthena Corporation...+4.56+8.53%
Data as of 3:59pm ET, 02/27/2017

Financials

Next reporting dateMay 3, 2017
EPS forecast (this quarter)$1.31
Annual revenue (last year)$109.0M
Annual profit (last year)-$2.4M
Net profit margin-2.17%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
John L. Higgins
President &
Chief Operating Officer
Matthew W. Foehr
Corporate headquarters
San Diego, California

Forecasts